Phathom Pharmaceuticals PHAT 深 沪
等待开盘 07-08 09:30:00 美东时间
11.55
+0.170
+1.49%
华盛通- 最 高12.05
- 今 开11.54
- 成交量 135.90万股
- 最 低 11.34
- 昨 收 11.38
- 总市值 9.21亿
- 52周最高 18.31
- 市盈率 静 --
- 换手率 1.70%
- 52周最低 7.61
- 委 比 92.70%
- 总股本 7975.60万
- 历史最高 64.54
- 量 比 1.54
- 振 幅 6.24%
- 历史最低 2.21
- 每 手 1
- 风险率 2.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phathom Completes Enrollment in Eosinophilic Esophagitis Trial
Phathom Pharmaceuticals ( ($PHAT) ) has shared an update. On June 23, 2026, Pha...
06-23 20:38
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults Phathom Pharmaceuticals completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) in adult eosinophilic esophagitis. Topline results for the 12-week double-blind portion are expecte
06-23 19:59
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) for treating eosinophilic esophagitis (EoE) in adults. The study, which enrolled 95 patients, is the first large, placebo-controlled trial of acid suppression therapy for EoE. Topline results are expected in Q4 2026. EoE is a chronic immune condition with limited approved therapies, often managed with proton pump inhibit...
06-23 11:59
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
06-17 18:24
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced that its management team will participate in three investor conferences in May and June 2026: the Craig-Hallum Conference in Minneapolis on May 28, the Jefferies Global Healthcare Conference in New York on June 3, and the Goldman Sachs Global Healthcare Conference in Miami on June 9. The company, focused on gastrointestinal disease treatments, markets vonoprazan-based products for GERD and H. pylori infection. Mo...
05-22 12:00
Phathom Pharmaceuticals shares are trading lower. The company reported Q1 financial results.
Phathom Pharmaceuticals shares are trading lower. The company reported Q1 finan...
04-30 23:15
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Phathom Pharmaceuticals (NASDAQ:PHAT) released first-quarter financial results ...
04-30 21:13
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $320.000 million-$345.000 million to $320.000 million-$345.000 million vs $331.417 million estimate.
04-30 19:02
